ViaMune is a preclinical-stage company and offers a fully synthetic vaccine platform that generates robust immune responses to tumor-specific targets. ViaMunes patented technology provides a unique path to targeting structures found only on tumor cells.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”” connections=”true” suffix=””]